Monoclonal antibody-mediated blockade of the MICA/B alpha-3 domain stabilizes NKG2D ligands in tumor cells and promotes NK cell recognition. Metastatic melanoma is significantly inhibited in the lungs of mice treated with the alpha-3 domain-specific
Traditionally, NK-cell mediated cytotoxicity assay is performed with release assays such as Chromium 51 release. In this work, we demonstrate a novel method to monitor long term NK cell-mediated cytotoxicity.
- Drive awareness to new scientific discoveries, understand work flows around these areas of focus and discuss tips and tricks to get the best results
Lucas Ferrari de Andrade, Ph.D.
Postdoc in the Wucherpfennig Lab, Department of Cancer Immunology and Virology
Dana-Farber Cancer Institute, Harvard Medical School
Lucas received in 2014 his PhD in Molecular and Cellular Biology by Universidade Federal do Parana, Brazil. During his PhD he trained for one year in NK cells and Cancer in the lab of Mark Smyth at QIMR Berghofer Medical Research Institute.
In the Fall of 2014, Lucas joined the lab of Kai Wucherpfennig at Dana-Farber to develop an antibody-based therapy for cancer. Now, Lucas is joining as a faculty member the Department of Oncological Sciences and Precision Immunology Institute
in the Icahn School of Medicine at Mount Sinai, New York, where he will characterize the NK cell-driven immunity and develop novel NK cell-based therapies for cancer.
Leo Chan, Ph.D.
Technology R&D Manager, Technology R&D and Collaboration
Leo Chan currently serves as the Technology R&D Manager at Nexcelom Bioscience LLC, Lawrence, MA. His research involves in the development of instrument and applications for the Celigo and Cellometer image cytometry system for detection
and analysis of cells for oncology and immunology research. He is a member of the American Association of Cancer Research and American Association of Immunologists. He received his B.S., M.S., and Ph.D. in Electrical and Computer Engineering
from the University of Illinois at Urbana-Champaign (2000-2008).